The prevention of pneumococcal disease by vaccines: promises and challenges (Q34218669)

31 July 2017

1 reference

title

The prevention of pneumococcal disease by vaccines: promises and challenges (English)

1 reference

31 July 2017

Poland GA

1

1 reference

31 July 2017

1 March 2001

1 reference

Infectious Disease Clinics of North America

31 July 2017

1 reference

31 July 2017

15

1 reference

31 July 2017

1

1 reference

31 July 2017

97-122

1 reference

Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : II. IMMUNOLOGICAL SPECIFICITY OF SYNTHETIC SUGAR-PROTEIN ANTIGENS.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Colonization by Streptococcus pneumoniae among human immunodeficiency virus-infected adults: prevalence of antibiotic resistance, impact of immunization, and characterization by polymerase chain reaction with BOX primers of isolates from persistent

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Vaccination and Revaccination with Polyvalent Pneumococcal Polysaccharide Vaccines in Adults and Infants

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Emergence of drug-resistant pneumococcal infections in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Efficacy of pneumococcal polysaccharide vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Epidemiology of pneumococcal serotypes and conjugate vaccine formulations

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Pneumococcal Vaccine: Dose, Revaccination, and Coadministration with Influenza Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

A strategy to improve the utilization of pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Effect of Haemophilus influenzae type B immunization on HIV viremia in HIV-seropositive adults

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Immunogenicity of pneumococcal conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Improving the use of pneumococcal vaccine through a strategy of hospital-based immunization: a review of its rationale and implications

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Influenza and pneumococcal immunization strategies for physicians

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Pneumococcal vaccination for older adults: the first 20 years

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Pneumococcal conjugate vaccination for adults: why it's important for children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Inefficacy of pneumococcal vaccine in a high-risk population

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Immunization of adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Polysaccharide conjugate vaccine responses in bone marrow transplant patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

The impact of vaccination strategy and methods of information on influenza and pneumococcal vaccination coverage in the elderly population

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Safety of revaccination with pneumococcal polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Should patients positive for HIV infection receive pneumococcal vaccine?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Assessments of Plasma HIV RNA and CD4 Cell Counts after Combined Pneumovax® and Tetanus Toxoid Vaccination: No Detectable Increase in HIV Replication 6 Weeks after Immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Pneumonia in old age; active immunization against pneumonia with pneumonococcus polysaccharide; results of a six year study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Pneumococcal Polysaccharide-Meningococcal Outer Membrane Protein Complex Conjugate Vaccine Is Immunogenic in Infants and Children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

New vaccines for the prevention of pneumococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Pneumococcal conjugate vaccines: review and update

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

The importance of G1m and 2 allotypes for the IgG2 antibody levels and avidity against pneumococcal polysaccharide type 1 within mono- and dizygotic twin-pairs

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Pneumococcal vaccine in normal children. Primary and secondary vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Effect of pneumococcal vaccine on morbidity from acute lower respiratory tract infections in Papua New Guinean children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Pneumococcal antibody levels one decade after immunization of healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Antibody to Capsular Polysaccharides of Streptococcus pneumoniae: Prevalence, Persistence, and Response to Revaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

IgG responses to protein-conjugated pneumococcal capsular polysaccharides in persons who are genetically incapable of responding to unconjugated polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Side effects associated with pneumococcal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

The burden of pneumococcal disease: the role of conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Underutilization of pneumococcal vaccine in nursing home in Washington State: report of a serotype-specific outbreak and a survey

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Safety of pneumococcal revaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Associations of prevaccination antibody levels with adverse reactions to pneumococcal and influenza vaccines administered simultaneously in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

IgG subclasses of pneumococcal antibodies--effect of allotype G2m(n)

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Pneumococcal vaccine failure

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Efficacy of pneumococcal conjugate vaccines in large scale field trials

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Pneumococcal disease: prospects for a new generation of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

The Clinical Effectiveness of Pneumococcal Vaccine in the Elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Use of influenza and pneumococcal vaccines in people with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Thymus-independent and thymus-dependent responses to polysaccharide antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Glycoconjugate vaccines. What next?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Equal IgG antibody response to pneumococcal vaccination in all stages of human immunodeficiency virus disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Influenza immunization of HIV-1-infected patients does not increase HIV-1 viral load

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970270-1

7 January 2021

10.1016/S0891-5520(05)70270-1

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11301826